eligibility_summary
Eligibility: CD20+ follicular lymphoma grade 1–3a, stage II bulky or III/IV, measurable disease (CT/MRI), ECOG 0–2, adequate marrow/hepatic. Part 1A: untreated FLIPI-1 3–5 or R/R, Part 1B: untreated FLIPI-1 3–5, Part 2: untreated FLIPI-1 0–5. Exclude CNS/leptomeningeal lymphoma, transformed high-grade/DLBCL, WM, grade 3b FL, CLL/SLL, recent major surgery/transplant, other active malignancy/serious conditions. Other criteria apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3, open-label trial in untreated follicular lymphoma comparing odronextamab + chemotherapy (CHOP or CVP) ± odronextamab maintenance vs rituximab + chemotherapy with rituximab maintenance. Odronextamab (REGN1979): IgG-based bispecific T‑cell–engaging antibody (anti‑CD20 × anti‑CD3) that binds CD20 on malignant B cells and CD3 on T cells to redirect cytotoxic T cells and deplete B cells. Rituximab: anti‑CD20 chimeric monoclonal antibody causing B‑cell depletion via ADCC/CDC/apoptosis. Chemotherapy: cyclophosphamide (alkylating agent, DNA crosslinks), doxorubicin (anthracycline, topoisomerase II inhibition/ROS), vincristine (vinca alkaloid, microtubule inhibitor), prednisone/prednisolone (glucocorticoid, lympholytic). Targets/pathways: CD20+ B cells, T‑cell CD3 activation, DNA damage, microtubules, glucocorticoid receptor.